• SideChannel recently released Enclave, its first software product
• The company acquired SideChannel in July 2022 and changed its name post-acquisition
• An industry benchmark study puts average CISO compensation at $463,000 annually, making SideChannel’s vCISO model attractive to its SMB target market
• According to IBM, the average cost to organizations of a cybersecurity breach is $4.2 million
• Cybersecurity Ventures reports a lack of trained professionals will leave 3.5 million cybersecurity positions unfilled by 2025, increasing demand for virtual security services

SideChannel (OTCQB: SDCH) simplifies cybersecurity for mid-market companies by matching them with highly experienced information security officers at a cost lower than building an in-house information security team or hiring a full-time CISO. SideChannel’s team of virtual Chief Information Security Officers (“vCISOs”) possesses a combined 400-plus years of experience in cybersecurity. They’ve honed their skills and abilities in places like Anthem, Dick’s Sporting Goods, Best Buy, TD Bank and the Pentagon. SideChannel lends this talent to clients, creating value in the form of a bespoke cybersecurity program perfectly sized for the growing enterprise. SideChannel is committed to creating top-tier cybersecurity programs for SMBs to help them protect their data and assets. To date, SideChannel has created more than 50 multi-layered cybersecurity programs for its clients. Reports show that cyberattacks on SMBs have increased in recent years, as organizations’ network attack surfaces have grown exponentially with remote and in-office workers increasingly relying on cloud environments, mobile devices, software applications and third-party suppliers to conduct business. SideChannel continues expanding its service offerings, workforce and customer base, attracting over 20 virtual CISOs to serve across industries including fintech, biotech, healthcare, manufacturing, legal, defense and technology services. The company is based in Worcester, Massachusetts. Market Opportunity An analysis from ReportLinker states that the global cybersecurity market is expected to grow from an estimated value of $173.5 billion in 2022 to $266.2 billion by 2027, recording a CAGR of 8.9% for the period. The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems, and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors driving cyber security market growth, according to the report. A lack of cybersecurity professionals and the budget constraints among SMBs and start-ups in developing economies are expected to hinder market growth. Cybercriminals are using automated techniques to attack SMBs’ networks to take advantage of their weak security infrastructures. To save money, time and resources, SMBs are seeking cybersecurity solutions. Enclave Enclave expands upon SideChannel’s cybersecurity service offerings by solving a pervasive network security problem with a simple tool. A comprehensive cloud and network security solution, Enclave enables IT teams to contain breaches faster, reduce network outages, minimize latency and strengthen overall security defense. Enclave creates the foundation for a Zero Trust network security model IT can build upon. With Enclave, IT can easily segment their company’s network, organize personnel and computing devices at the employee workload level, and implement security controls across all network segments. Enclave was designed and purpose built to serve the growing security needs of SMBs, a traditionally underserved market that is more prone to cyberattacks but has limited protection due to smaller budgets, inadequate IT security staffing and a lack of cybersecurity awareness among top executives. Enclave is an affordable and effective network security solution that shrinks the attack surface area exposed to a cyber intruder and significantly reduces the amount of effort required to operate securely. Management Team Brian Haugli is CEO of SideChannel. He has led programs for the U.S. Department of Defense, the Pentagon, and Fortune 500 companies. He is an expert on National Institute of Standards and Technology guidance, threat intelligence implementations and strategic organizational initiatives. He is a professor at Boston College, Woods College of Advancing Studies Master’s Program in Cybersecurity. He is also a contributing author for the Wiley book ‘Cybersecurity Risk Management’. Ryan Polk is CFO at SideChannel. He has been the principal of Perissos Partners, an executive consulting firm, since June 2017. He also served in executive roles in the portfolio companies owned by Lacy Diversified, with combined revenue approaching $2 billion. He served as the Vice President for Corporate Financial Planning and Analysis for Brightpoint, a publicly traded, Fortune 500 mobile device logistics company. He earned a bachelor’s degree in accounting and industrial management from Purdue University. Nicholas Hnatiw is Chief Technology Officer at SideChannel. Prior to joining the company, he served as the technical director for network operations supporting U.S. Cyber Command, U.S. Intelligence Agencies and other Department of Defense research organizations. He was also the CEO of Loki Labs, a cyber security firm. He earned a bachelor’s degree in computer engineering and computer science at the University of Massachusetts, Amherst. Bill Roberts is SideChannel’s CISO. He most recently served as the vice president, IS & CISO for Hologic Inc., a global medical device company, where he established cyber security and IT compliance programs. Prior to Hologic, he was vice president of information security for Cytyc Corporation, which was acquired by Hologic in 2007. At Cytyc, he managed global IT as the company grew from 140 employees to 1,500 and from $40 million in revenue to over $750 million. For more information, visit the company’s website at www.SideChannel.com. NOTE TO INVESTORS: The latest news and updates relating to SDCH are available in the company’s newsroom at https://ibn.fm/SDCH

• With the recently passed Inflation Reduction Act, Correlate looks to achieve significant net gains
• The company just posted a significant revenue bump from $236,690 in Q2 2022 to $2,313,577 in Q3 2022, plus shows project opportunities of up to $194 million
• Todd Michaels, Correlate’s CEO, has also noted the company’s finalized M&A plans through Q2 2023, integral to scaling up the size and overall value of its projects and further growing revenue
• In September, the company entered into a non-binding letter of intent to acquire Vermont-based Aegis Renewable Energy Inc., which, once finalized, will present Correlate with new strategic abilities to explore the bludgeoning Northeast renewable energy market

Correlate Infrastructure Partners (OTCQB: CIPI), a tech-enabled development, finance, and fulfillment platform for distributed energy solutions across North America, just released its financial report for the third quarter of the 2022 financial year (“Q3 2022”). Of obvious note was the significant bump in revenue from $236,690 in Q2 2022 to $2,312,577. While speaking during the announcement, Todd Michaels, Correlate’s CEO, lauded the company’s performance and expressed his optimism for the company’s future, particularly with the enactment of the Inflation Reduction Act (https://ibn.fm/wVfqP). Mr. Michaels acknowledged the Act, citing its benefits to clients and investors in the renewable energy space, reporting that the move will be a significant net gain for the company and integral in opening it up to new markets in 2023. “The Inflation Reduction Act enacted in late August provided new tax incentives that reduce costs for clients and/or elevate returns to investors; this led to larger contract sizes with redesigns to domestic content,” noted Mr. Michaels. “While this meant delaying some project starts, it will be a big net gain, and will open new markets for us in 2023,” he added. The Inflation Reduction Act was designed to offer renewable technologies tax credits. While it promises immediate results and benefits, the most significant impact is projected to be felt toward the end of the decade once supply-chain issues are fixed. For example, through this Act, it is estimated that solar power plants built between 2022 and 2030 will generate over 364 gigawatts of electricity, which is more than three times the capacity of all US solar plants in operation in 2021 (https://ibn.fm/Gupzo). Currently, Correlate has project opportunities valued at up to $194 million, with projects in development that have been awarded agreements and contracts that have been executed and are under installation. With the implemented Act, it looks to significantly scale up its projects’ size and overall value, ultimately growing its revenue and creating even more value for its shareholders. This will also be achieved by Correlate’s ambitious M&A plan, which Mr. Michaels notes the company has already finalized. “With this in mind [anticipated project delays], we have finalized our M&A plans through Q2 2023 and seek to close our first acquisition by year-end,” noted Mr. Michaels. In September, Correlate entered into a non-binding letter of intent to acquire Vermont-based Aegis Renewable Energy Inc., a leading commercial, industrial, and community solar company focused on solar project development and engineering, procurement, and construction (“EPC”). Through this acquisition, Correlate hopes to capitalize on new strategic abilities to explore the bludgeoning Northeast renewable energy market where some of the states in the region, such as Vermont, have set goals to meet 90% of their energy needs with renewable sources by 2050 (https://ibn.fm/f5DuI). Correlate remains optimistic about its performance going forward and looks to capitalize on new and existing opportunities to achieve its short-term and long-term goals. Mr. Michaels is confident that the recently-implemented Inflation Reduction Act will play an integral role in the company’s growth, expansion of its opportunity pipeline, and value creation for its shareholders. For company information, visit the company’s website at www.CorrelateInfra.com, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income www.CorrelateInfra.com/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals www.CorrelateInfra.com/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• Ammonia is a highly efficient carrier of both hydrogen and nitrogen, with nitrogen being a critical component to fertilizers and world food production, but traditional ammonia production results in large greenhouse gas emissions
• FuelPositive’s carbon-free “green ammonia” production technology represents an environmentally superior way of producing ammonia
• The company’s confidence in its product has seen it go the extra mile to develop on-farm containerized, green ammonia production systems, that can be leveraged on a smaller scale to create green ammonia for agricultural fertilizers on-site

FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF), a company focused on licensing, partnership, and acquisition opportunities related to energy-efficient, climate-safe, and sustainable solutions and sustainability, recognizes the rapidly growing demand for green technologies. The need is formalized in the UN’s 2050 Net Zero Goal for the drastic reduction of greenhouse gas emissions (https://ibn.fm/JXpj9). While there is a warranted push towards solar and wind energy, the company is bringing something new and viable to the discussion: green ammonia. FuelPositive’s green ammonia offers something different, a commercially viable and sustainable green solution for use across various industries and applications such as agriculture, transportation, and energy generation. Ammonia is a highly efficient carrier of both hydrogen and nitrogen. While hydrogen is critical to prospects for a hydrogen economy, nitrogen is a critical component to fertilizers and world food production. However, traditional ammonia production results in large greenhouse gas emissions. FuelPositive’s carbon-free green ammonia production technology offers an innovative alternative solution to the concerns associated with traditional ammonia generation, minimizing greenhouse gas emissions. As a result, it offers technology to address storage problems associated with hydrogen production and use, and technology to allow the production of ammonia for agricultural fertilizers with minimum greenhouse gas emissions. In the field of agriculture, FuelPositive’s confidence in its product has seen it go the extra mile to develop on-farm, containerized, green ammonia production systems that can be leveraged on a smaller scale to create on-site green ammonia. This is a huge step for more environmentally friendly agriculture, since 80% or more of all ammonia produced is used for fertilizing agricultural crops (https://ibn.fm/Yh4xC). For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF

• BiondVax summarizes collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen to discover and develop nanosized antibody (NanoAb) therapies that address underserved and growing markets, including COVID-19, psoriasis, asthma, psoriatic arthritis and wet macular degeneration.
• The global COVID-19 therapy market was valued at $16.8 billion in 2021 and is expected to grow at a CAGR of 20% during the forecast period, resulting in a value of $35.42 billion by 2025
• The psoriasis market is experiencing a higher-than-expected demand across all regions due to the increasing geriatric population and the growing prevalence of plaque psoriasis and psoriatic arthritis resulting in an anticipated value of $47.24 billion by 2029

Joshua E. Phillipson, BiondVax Pharmaceuticals (NASDAQ: BVXV) Director of Communications and Investor Relations, recently presented the company’s corporate presentation to investors attending the LD Micro Main Event hosted by SRAX, Inc. at the Luxe in Los Angeles and online via Sequire Virtual Events platform October 25-27, 2022. The LD Micro Main Event, known as the “Woodstock” of the micro-cap world, has been showcasing the next big names in the space for the last 15 years. Phillipson was provided with 25 minutes on the main stage to offer investors an in-depth look at the company. The video is available at https://me22.sequireevents.com/recording?session_id=c2bc57cd-a925-43b2-8441-9f927a64b4f7 (free registration required).

BiondVax is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases. BiondVax is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, psoriasis, asthma, psoriatic arthritis and wet macular degeneration. The company currently collaborates with the prestigious Max Planck Institute for Multidisciplinary Sciences (“MPG”) and the University Medical Center Göttingen (“UMG”), both in Germany.

Phillipson shared the company’s significant potential for value creation with the investors in attendance and online during the LD Micro event. BiondVax is targeting a massive, validated, addressable market with a pipeline of de-risked NanoAbs with a lead candidate to treat COVID-19 as a self-administered inhaled therapy that has a strong competitive edge. With seasoned scientific leadership and state-of-the-art laboratories and GMP biologics manufacturing facility, the company is well-positioned to bring innovative therapies to market with unique large pharma competencies. Key catalysts for BiondVax are expected in 2022 and 2023.

The company is tapping into the markets of multiple indications to create avenues where there is an unmet need for pharmaceutical therapies. The global COVID-19 therapy market was valued at $16.8 billion in 2021 and is expected to grow at a CAGR of 20% during the forecast period, resulting in a value of $35.42 billion by 2025 (https://ibn.fm/qgzIB). Additionally, BiondVax is planning to target the psoriasis treatment market, which was valued at $24.33 billion globally in 2021. This market is projected to grow to $47.24 billion by 2029 at a CAGR of 8.7%. The psoriasis market is experiencing a higher-than-expected demand across all regions due to the increasing geriatric population and the growing prevalence of plaque and psoriatic arthritis (https://ibn.fm/rOSNg).

The company brings significant clinical and commercial advantages to the collaboration with Max Planck including:

• Infectious disease and recombinant protein drug development experience from lab to Phase 3 clinical trial
• Manufacturing quality and international regulatory experience
• A GMP biologics manufacturing facility well suited to NanoAb production
• Top-tier big pharma and biotech leadership experience
• World-class science and access to leading scientists
• NanoAb platform for the development of promising potent therapeutics
• Exclusive rights to exclusive worldwide licenses covering patented NanoAbs and their manufacturing

BiondVax’s de-risked NanoAbs feature a favorable path to market compared to the risks associated with traditional drug treatments. Compared to monoclonal antibodies (“mAbs”) and oral therapies, the company provides multiple crucial advantages that offer convenience and flexibility backed by clinical benefits.

For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

• The National Brain Tumor Society anticipates that more than 13,000 Americans will receive a GBM diagnosis during 2022, accounting for 49.1% of all primary malignant brain tumors
• CNS announced the first patient in Europe has been enrolled and dosed in the global trial to evaluate Berubicin for the treatment of GBM
• Berubicin is a novel anthracycline and the first to appear to cross the blood-brain barrier
• The global GBM treatment market is expected to reach a value of $4.2 billion by 2028, driven by the increased approval granted by the FDA for novel GBM treatment therapies

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical stage biotechnology company specializing in the development of novel treatments, announced that the first patient in Europe has been enrolled and dosed in France in the company’s ongoing potentially pivotal global trial to evaluate Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. According to the National Brain Tumor Society, more than 13,000 Americans are expected to receive a GBM diagnosis during 2022, which accounts for 49.1% of all primary malignant brain tumors (https://ibn.fm/RKJHr).

CNS Pharmaceuticals has opened 29 clinical sites of the 68 sites selected across the United States, Italy, France, Spain, and Switzerland. The company is planning a non-binding futility analysis, which will be performed after approximately 30 to 50% of all planned patients have completed the primary endpoint at six months which is expected mid-year 2023. The review will include additional evaluation of safety as well as secondary efficacy endpoints, with no pause to enrollment during the interim analysis.

According to CEO John Climaco, the CNS Pharmaceuticals team worked tirelessly to expand its Berubicin clinical trial globally, and the enrolment and dosing of the first patient in France shortly after the opening of the site is a notable accomplishment and confirmation of the team’s commitment to driving the program forward (https://ibn.fm/K9IUE).

“I am pleased with the progress made and remain committed to building on this momentum. We expect to enroll and dose additional patients across our clinical trial sites in Europe and advance toward the much-anticipated inflection point, which is the interim analysis,” Climaco added.

The global GBM treatment market was valued at $2.14 billion in 2020 and is expected to grow at a CAGR of 8.8% and reach an estimated value of $4.2 billion by 2028. The market’s growth is expected to be driven by the increased approval for novel therapies for GBM treatment. The special designation granted by the FDA for investigational new drugs is expected to help expedite the approval process and commercialization of these therapies (https://ibn.fm/ZxByq).

Berubicin is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier (based upon pre-clinical data and limited clinical data) and is currently being evaluated in the potentially pivotal study evaluating efficacy and safety for GBM treatment. This potentially pivotal study is an adaptive, multicenter, open-label, randomized, and controlled study in adult patients with recurrent GBM after the failure of standard first-line therapy. The study’s primary endpoint is Overall Survival (“OS”), an endpoint the FDA has recognized as a basis for approval of oncology drugs when a statistically significant improvement can be shown relative to a randomized control arm.

CNS’s study will compare Berubicin to a standard of care (Lomustine), with a 2 to 1 randomization of patients to receive one of the two drugs. The recently amended protocol expands eligibility to patients who received additional treatments as a form of first-line therapy. The FDA has granted the company Fast Track Designation for Berubicin, enabling more frequent interactions with them to guide expediting the development and review process. The FDA has also granted CNS Orphan Drug Designation, which may provide seven years of marketing exclusivity upon approval of an NDA.

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

The RHK Capital 2022 Disruptive Growth Conference, being held at the offices of Reed Smith in New York City, invites investors, capitalists, life science companies, growth companies and budding enterprises, for an interactive session of learning, networking, exchange of ideas, and business collaborations, spread over two days. The RHK Capital 2022 Disruptive Growth Conference offers a robust forum and an exclusive opportunity to discover disruptive growth companies. Up to 30 senior management teams from highly reputed companies will pitch their businesses to over 200 institutional investors, accredited investors, family offices, Wall Street analysts, financial advisors, broker-dealer wealth managers and RHK Capital clients. The conference commences with registrations on the first day, followed by panel discussions, company presentations, and buffet lunches, followed again by conference events. The RHK 2022 Disruptive Growth Conference offers investors the forum to discover growth companies with disruptive technologies and business models covering the following sectors: communications, consumer, energy/alternative energy, healthcare, industrial, life sciences, natural resources, and technology. Investors can meet the company executives in one-to-one sessions to analyze, assess, and learn about company goals and future aspirations. In the past, many eminent companies and investors have been a part of this show. They continue to visit every year to gain a better business perspective, new clients and opportunities. Budding companies and new entrepreneurs looking for investors can fix personal meetings to discuss their business goals in depth with these industry leaders. The RHK Capital conferences are curated keeping the attendees in mind. The organizers specialize in delivering tailored experiences through these personalized conferences and research-based events. Their educational programming sessions are hosted by dignitaries who guide the attendees and discuss pivotal topics that are expected to shape the future of industries. At this forum, micro-cap companies take the opportunity to make presentations on their goals and future expansion plans, engaging directly with investors through one-on-one discussions, presentations, and dialogues, developing and strengthening business ties. Investors and presenting companies repeatedly join with every event owing to the immense response that they receive. Attendees can be a part of the personalized sessions with industry heavyweights to speak on numerous important business trends and strategies. The event encourages small-cap and micro-cap companies that show growth potential, to connect with investors and build long-term profitable business ties. To know more, please visit https://ibn.fm/eAtz4.

• Vision Energy is in advanced stages of planning for construction and delivery of Northwestern Europe’s first import, storage and handling terminal designed exclusively for hydrogen carriers, renewable energy products and low-carbon fuels
• Vision Energy, through its wholly owned subsidiary Evolution Terminals BV, just announced partnership with Linde Engineering, a leading global industrial gases and engineering company, to deliver preliminary Front-End Engineering and Design (“FEED”) services to the project
• Green Energy Terminal Project will accelerate and advance the energy transition and facilitate Northwestern Europe’s ambition to achieve Net Zero through carbon-abatement and adoption of hydrogen as a core feedstock and fuel

Committed to providing the lowest carbon solutions with the highest yield hydrogen production, Vision Energy (OTCQB: VIHDD) just announced another milestone in the development of the company’s pioneering Green Energy Terminal in North Sea Port of Vlissingen, the Netherlands. In a recent press release Vision Energy reported it has entered into a cooperation agreement with Linde Engineering to accelerate engineering efforts for the company’s pioneering Green Energy Terminal in North Sea Port of Vlissingen, the Netherlands. Linde Engineering, a leading global industrial gases and engineering company with 2021 sales of $31 billion, will deliver preliminary Front-End Engineering and Design (“FEED”) services to the project including design and engineering of 150,000 cubic meters (“CBM”) of Green Ammonia (“NH3”) storage, truck and barge loading facilities, ship loading and unloading facilities, as well as utilities, infrastructure and buildings.

With its strategic location between the Scheldt River and the North Sea, Vlissingen has been an important harbor for centuries and is now an economic driving force serving all of Europe. Vision Energy is in the advanced stages of planning the construction and delivery of Northwestern Europe’s first import, storage and handling terminal designed exclusively for hydrogen carriers, renewable energy products and low-carbon fuels. Total capacity under Phase 1 is for up to 400,000 CBM including 150,000 CBM allocated to Green Ammonia, 180,000 CBM allocated to Renewable Methanol and 70,000 CBM allocated to Biofuels.

“Our Green Energy Terminal Project will accelerate and advance the energy transition and facilitate Northwestern Europe’s ambition to achieve Net Zero through carbon-abatement and adoption of hydrogen as a core feedstock and fuel,” stated Andrew Hromyk, Vision Energy CEO, “Our cooperation with Linde Engineering marks a critical milestone in our development, to deliver this world-class project with the vast global expertise Linde possesses.”

An integrated energy company developing assets and solutions for the commercial, industrial and transportation sectors, Vision Energy leverages a proven track-record to facilitate low-carbon energy production, supply and distribution. The company pursues reliable offtake relationships and operating partnerships with energy industry participants and end users seeking carbon abatements across feedstock and fuels. Vision Energy is committed to providing low carbon energy solutions with the highest yield, and where possible, projects are designed to utilize existing gas and power infrastructure to integrate and facilitate import and or distribution of reduced-carbon energy to domestic and global supply chains.

In a world wracked with rising temperatures and increasing climate challenges, Vision Energy is delivering solutions and opportunity. Development of its Green Energy Terminal in Northwestern Europe will lessen dependence on Russian oil, have a positive impact on the economy and help transition to a carbon free future. Expect to hear lots more about Vision Energy in the months and years to come.

For more information, visit the company’s website at https://visionenergy.com/.

NOTE TO INVESTORS: The latest news and updates relating to VIHDD are available in the company’s newsroom at https://ibn.fm/VIHDD

• Worldwide initiatives to slash carbon emissions, recently bolstered by the Inflation Reduction Act in the United States, are underpinned by EV uptake, which needs innovation to scale and reach critical mass
• Hillcrest Energy Technologies has developed a cutting-edge 250-kilowatt, 800-volt Silicon Carbide (“SiC”) EV inverter that has captured the attention of leading firms
• Hillcrest has recently inked new partnerships, including one with a global Tier 1 automotive supplier, for the purpose of commercializing new inverters for electric mobility applications

With 1.4 billion vehicles in use today and around 1 percent of them powered by electricity, the move to decarbonize the transportation industry is accelerating yet also has far to go. The U.S. Inflation Reduction Act signed into law in August is arguably the most significant piece of U.S. legislation designed to accelerate adoption of electric vehicles (“EVs”) and promote innovation, which is going to have to come from all angles to meet global carbon goals in the next eight years. Sure, it’s simple to say, “everyone just needs to get an electric vehicle,” but it is more complicated than that. Consider that the Argonne National Laboratory is constantly analyzing data to try and figure out where to put new charging stations to ensure fair access and that research is still relatively nascent in understanding temperature-related fluctuations in battery performance. And that’s just one observation from a 30,000-foot view. At a more granular level, new power conversion technologies, like those of Hillcrest Energy Technologies (CSE: HEAT) (OTCQB: HLRTF), are being developed to improve efficiency and curtail EV costs. Hillcrest, a one-time fossil fuels producer, has ditched that model to pivot into clean energy technologies. The company specializes in developing control systems and electric power conversion devices for powertrains and charging applications in addition to renewable energy generation and storage systems. As noted by Hillcrest CEO Don Currie, the company is at an inflection point after developing and successfully testing a cutting-edge 250-kilowatt (“kW”), 800-volt (“V”) Silicon Carbide (“SiC”) EV traction inverter prototype. The inverter’s adaptable design gives Hillcrest a competitive advantage with the flexibility to quickly meet customers’ needs with a smaller, lighter, and more powerful product. “[Our] highly adaptive power conversion technology is at an exciting stage of growth and development, evidenced in part by our two recent strategic partnerships including a global Tier 1 automotive supplier,” said Currie in a recent press release announcing Hillcrest had retained an investor relations firm to help with outreach. In the automotive industry, Tier 1s are operations that supply parts and systems directly to an automaker such as Tesla, Ford, Rivian, Volkswagen, et al. Confidentiality agreements keep Hillcrest from being able to reveal the name of its new Tier 1 partner, but it can disclose that the two have a memorandum of understanding to collaborate to integrate an optimized version of Hillcrest’s 250kW, 800V inverter into a future powertrain system. The goal is commercialization of a nominal 350kW product that capitalizes on the unique properties of Hillcrest’s highly efficient inverter. That news came on the heels of a new partnership with Hercules Electric Mobility, Inc. Hercules, an emerging company revolutionizing electric mobility in both marine and recreational vehicles, is also interested in working with Hillcrest to access its inverter tech. The two are collaborating on building and commercializing a 250kW, 800V inverter optimized for a Hercules electric powertrain. The collaborative agreements speak volumes as to the quality of the Hillcrest technology, as well as the company’s adaptable nature and flexible technology design that facilitates optimization and seamless integration with new products. For more information, visit the company’s website at www.HillcrestEnergy.tech. NOTE TO INVESTORS: The latest news and updates relating to HLRTF are available in the company’s newsroom at https://ibn.fm/HLRTF

• BEAT named winner of the 2022 Cardiovascular Innovations (“CVI”) Innovation Summit and Shark Tank Competition
• Company’s presentation included an overview of its HeartBeam AIMI™ platform, which aids in more precise heart attack diagnosis
• HeartBeam is building an intellectual-property portfolio focused on enabling 12-lead electrocardiogram (“ECG”) diagnostics outside of a medical setting

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, has been named winner of the annual Cardiovascular Innovations (“CVI”) 2022 Innovation Summit and Shark Tank Competition (https://ibn.fm/ftaNr). The annual conference focuses on innovative health solutions for cardiology clinicians who participate in the care of patients with coronary, peripheral and structural cardiovascular diseases; awards presented at the conference recognize state-of-the-art cardiac technologies. “We are proud that HeartBeam has been recognized for our unique approach to heart attack diagnosis,” said HeartBeam CEO and founder Branislav Vajdic, PhD. “Our goal is to provide a solution that offers both healthcare professionals and patients peace of mind regarding their diagnosis and treatment plan.” The company was invited to present at the conference, which was held in Denver on July 21, 2022. The company’s chief business officer, Jon Hunt, PhD, delivered an address entitled “Medical Grade Heart Attack Detection.” The presentation included an overview of the company’s HeartBeam AIMI platform, which aids in more precise heart attack diagnosis. HeartBeam was one of several companies presenting at the conference; the awards were determined by judges that included expert cardiologists along with veterans from leading companies. The company, which has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, has made a mark for itself in the cardiac care field by building an intellectual-property portfolio focused on enabling 12-lead ECG diagnostics outside of a medical setting. Most recently, HeartBeam announced that it was issued a new patent, which enables generation of a synthesized 12-lead ECG by the HeartBeam AIMIGo(TM) credit card-sized device, by the United States Patent and Trademark Office (“USPTO”) (https://ibn.fm/BERLz). “This patent provides additional intellectual property protection for our breakthrough AIMIGo technology offering 12-lead ECG capability in the form of a credit card-sized device with the same footprint as the single-lead products currently in the market today,” said Vajdic. “Our 12-lead AIMIGo technology, which is part of our granted patent, offers the potential to bring a level of diagnostic accuracy consistent with the current 12-lead ECG standard of care. This could reduce the critical time to intervention for heart attack patients, saving lives and reducing healthcare costs by ruling out a heart attack and reducing the number of emergency room visits.” The HeartBeam AIMI-platform technology is anticipated to assist healthcare professionals in identifying patients who present with chest pain to facilitate rapid detection of a heart attack and determine an appropriate treatment regimen. Chest pain is the second most common reason for an emergency-department visit, with high costs associated with these visits. HeartBeam’s technology may offer more accurate heart attack detection to triage patients and expedite treatment. The HeartBeam technology platform has not yet been evaluated by the FDA and is not approved for clinical use in the USA or other global geographies. For more information, visit the company’s website at www.HeartBeam.com. NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

• Cepton signed binding agreement with established automotive lighting tier 1 supplier Koito for investment of $100 million to bolster its next stage of growth
• Agreement penned on October 27, 2022, marks the third investment from this long-term automotive Tier 1 partner and existing shareholder since 2020
• Lidar market expected to grow rapidly to reach $59 billion by 2030; Cepton appears to continue leading as a prominent figure, as it works toward commercialization and mass market deployment of its lidar sensors

Following a previously reported letter of intent from Koito Manufacturing Co., Ltd. (TSE:7276), Cepton (NASDAQ: CPTN) has announced that it has entered into a binding investment agreement for a $100 million investment from its long-term automotive Tier 1 partner and current shareholder (https://ibn.fm/LjTSk). This Silicon Valley innovator and leader in high-performance lidar solutions intends to use this investment — Koito’s third since 2020 — to fund the company’s next growth stage as it looks to execute its vision to scale lidar technology for mass deployment. Under the terms of the Investment Agreement, unanimously approved by Cepton’s board of directors, Koito will purchase $100 million of convertible preferred stock. This stock will be convertible, beginning on the first anniversary of the issue date, into shares of Cepton’s common stock at an approximate initial conversion price of $2.23 per share, representing a 10.0% premium to Cepton’s volume-weighted average price over the trailing 20 trading day period. As well as a 13.4% premium 14.4% 30-day VWAP and a 25.5% 90-day VWAP. The company expects to close the investment in the first quarter of 2023, subject to the approval of Cepton’s shareholders and satisfaction of relevant closing conditions. More information regarding the key terms of the investment is included in a Form 8-K that Cepton recently filed with the US Securities and Exchange Commission (https://ibn.fm/tnrlO). Cepton and Koito have had an established history of collaboration, including one that has been crowned with notable success, such as a significant ADAS lidar series production award on the General Motors business. In September 2022, the company received a Letter of Intent for up to $100 Million investment from this automotive lighting leader to boost Cepton’s balance sheet and its manufacturing and supply chain capabilities to meet the expected increase in demand amid the rapidly growing lidar market. “We are excited to further strengthen our partnership with Koito and remain deeply grateful for Koito’s continued support. This investment solidifies Cepton’s financial position and allows us to continue our execution excellence as we focus on commercialization and mass market deployment of our lidar sensors,” said Dr. Jun Pei, Cepton’s Co-Founder and CEO. Mr. Michiaki Kato, Koito’s President, appears equally enthusiastic about deepening what already looks like a successful collaboration. “We are pleased to announce our third investment in Cepton as we work towards developing and commercializing next-generation automotive sensor technologies. Our partnership has developed over the years and Cepton remains a critical partner for us. This investment serves as a testament to our commitment towards Cepton and bringing lidar-based ADAS and AV systems to everyday vehicles,” he said. While the lidar history goes back to the 1960s, when it was developed for aerospace and defense purposes, it was not until the 2000s that lidars started to be deployed in R&D automotive applications. In recent years, a growing number of players have focused on automotive applications, especially autonomous vehicles (https://ibn.fm/n7w3w). Although lidar used to be expensive, just like many other technologies at the pre-scale stage, the times are rapidly changing as the automotive industry evolves. Nowadays, lidar companies collaborate with leading automakers to make the technology more efficient and affordable, driving the cost down to as little as three digits. For example, Cepton expects to scale its lidar technology through its ADAS lidar series production award with Koito on the General Motors business. Other lidar companies have also announced series production awards from other OEMs. As a result, according to Cepton’s founder and CEO, costs are dwindling across the board (https://ibn.fm/4cLC9). Since 2020, when the autonomy levels started moving towards L3, the lidar industry had been progressing at an accelerated rate, attracting increasing investor attention, and receiving significant investments. It appears that the lidar industry is on the verge of mass-market adoption. High-performance, safe, and affordable lidar is expected to be deployed at a large scale in consumer vehicles — something Cepton has prided itself in as being a frontrunner of safety and efficiency for all classes (https://ibn.fm/c2KWm). As a result, the addressable market for lidar could grow to $59 billion by 2030, of which $50 billion is in ADAS applications. When Dr. Pei founded Cepton in 2016, his vision was to make lidar scalable. With continuous innovations driven by OEM requirements, the company seeks to bring lidar into everyday passenger cars, not just the luxury segment. For more information, visit the company’s website at www.Cepton.com. NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN